Published in Leuk Lymphoma on November 07, 2001
Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry. Eur J Histochem (2015) 0.96
CLEC5A (MDL-1) is a novel PU.1 transcriptional target during myeloid differentiation. Mol Immunol (2010) 0.88
BIRC6 (APOLLON) is down-regulated in acute myeloid leukemia and its knockdown attenuates neutrophil differentiation. Exp Hematol Oncol (2012) 0.80
ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell (1998) 8.99
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol (2004) 3.29
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol (2006) 2.72
The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer (2001) 2.67
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40
Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood (1994) 2.24
Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol (2002) 2.14
Prognostic factors in metastatic breast cancer. Cancer Clin Trials (1981) 1.96
Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol (2003) 1.94
1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A (1987) 1.89
Historical demography of Mullerian mimicry in the neotropical Heliconius butterflies. Proc Natl Acad Sci U S A (2004) 1.65
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter? J Clin Oncol (1999) 1.47
Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol Endocrinol (1990) 1.40
Glucocorticoids downregulate gene expression of GM-CSF, NAP-1/IL-8, and IL-6, but not of M-CSF in human fibroblasts. Blood (1992) 1.36
Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Ann Hematol (2000) 1.32
Analysis of somatic mutations at human minisatellite loci in tumors and cell lines. Genomics (1989) 1.28
Transcriptional and posttranscriptional modulation of myeloid colony-stimulating factor expression by tumor necrosis factor and other agents. Mol Cell Biol (1988) 1.27
Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. J Clin Invest (1995) 1.25
Quantitative analysis of beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA and their comparison as control transcripts for RT-PCR. Mol Cell Probes (2002) 1.20
Uncertain identity of doxorubicin-resistant MCF-7 cell lines expressing mutated p53. J Natl Cancer Inst (2000) 1.19
Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett (2007) 1.17
Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol (2004) 1.17
Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ (2002) 1.16
Aggressiveness of HNSCC tumors depends on expression levels of cortactin, a gene in the 11q13 amplicon. Oncogene (2008) 1.16
TrkC signaling is activated in adenoid cystic carcinoma and requires NT-3 to stimulate invasive behavior. Oncogene (2012) 1.14
Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol (2009) 1.12
Constitutive mRNA and protein production of macrophage colony-stimulating factor but not of other cytokines by synovial fibroblasts from rheumatoid arthritis and osteoarthritis patients. Br J Rheumatol (1994) 1.10
Epstein-Barr virus-associated anaplastic large cell lymphoma in renal transplant patients. Am J Clin Pathol (1992) 1.10
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer (1986) 1.10
Sequence variation of a novel heptahelical leucocyte receptor through alternative transcript formation. Biochem J (1995) 1.09
Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ (2007) 1.09
Assessment of clonality in human tumors: a review. Cancer Res (1990) 1.08
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene (2012) 1.08
Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer (2005) 1.07
Granulocyte-macrophage colony-stimulating factor. Sensitive and receptor-mediated regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral blood lymphocytes. J Clin Invest (1987) 1.07
Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene (2006) 1.06
p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. Int J Cancer (2000) 1.04
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1997) 1.04
Melanoma: chemotherapy. Br Med Bull (1995) 1.04
G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer (1997) 1.04
Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood (1995) 1.02
Hybrid incompatibility is consistent with a hybrid origin of Heliconius heurippa Hewitson from its close relatives, Heliconius cydno Doubleday and Heliconius melpomene Linnaeus. J Evol Biol (2005) 1.01
Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene (1997) 1.01
Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer (1999) 1.01
Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. Br J Cancer (2013) 1.00
The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. Oncogene (1995) 1.00
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene (1998) 0.99
Induction of Bim limits cytokine-mediated prolonged survival of neutrophils. Cell Death Differ (2009) 0.99
Implementation of the JACIE standards for a haematopoietic progenitor cell transplantation programme: a cost analysis. Bone Marrow Transplant (2004) 0.98
cDNA cloning of human N-Oct3, a nervous-system specific POU domain transcription factor binding to the octamer DNA motif. Nucleic Acids Res (1993) 0.98
Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol (1993) 0.98
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2000) 0.97
S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br J Cancer (2004) 0.97
A myeloperoxidase cDNA clone identifies an EcoRV RFLP. Nucleic Acids Res (1990) 0.97
[Stenosing ganglioneuromatosis of the small intestine with ileus and ileal rupture]. Schweiz Med Wochenschr (1981) 0.95
Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res (2000) 0.95
The use of allelic expression differences to ascertain functional polymorphisms acting in cis: analysis of MMP1 transcripts in normal lung tissue. Ann Hum Genet (2005) 0.95
Id2 expression increases with differentiation of human myeloid cells. Blood (1996) 0.93
DAPK2 is a novel E2F1/KLF6 target gene involved in their proapoptotic function. Oncogene (2008) 0.93
PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity. Oncogene (2008) 0.93
Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis. Cancer Res (1999) 0.92
Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochem Biophys Res Commun (2000) 0.92
A randomized crossover trial assessing patient preference for two different types of portable infusion-pump devices. Ann Oncol (1999) 0.91
The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1. Leukemia (2010) 0.91
Clonal analysis of human tumors with M27 beta, a highly informative polymorphic X chromosomal probe. J Clin Invest (1992) 0.90
Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours. Lung Cancer (2001) 0.90
Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anticancer Drugs (1995) 0.90
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies. J Clin Oncol (1994) 0.89
Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol (1997) 0.89
Efficiency of adenovirus-mediated gene transfer to oropharyngeal epithelial cells correlates with cellular differentiation and human coxsackie and adenovirus receptor expression. Hum Gene Ther (2000) 0.89
Psychogenic purpura, idiopathic thrombocytopenic purpura, and platelet dysfunction in the same patient. J Clin Psychiatry (1986) 0.89
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol (2001) 0.89
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Ann Oncol (2007) 0.89
Factors associated with transfusion requirements during treatment for acute myelogenous leukemia. Ann Hematol (1993) 0.88
Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer (2004) 0.88
Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. Int J Cancer (1992) 0.88